Search British Patient Capital
Popular Search placeholder

British Patient Capital announces £15m investment in Quantexa’s $175 million Series F Investment Round

Press release 05 March 2025

British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £15m follow on investment in Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors.

British Patient Capital initially had exposure to Quantexa via its commitment into Dawn Capital’s third fund. In 2020, it co-invested alongside Dawn in the company’s Series C investment round, and has since invested in the company’s Series D, Series E, and now Series F.

The round was led by Teachers’ Venture Growth (“TVG”), which is part of the CAD$255bn international investor Ontario Teachers’ Pension Plan.

This milestone is fuelling Quantexa’s progress against its mission to help enterprises and government agencies across multiple markets stay ahead in the race for AI-driven decision intelligence.

The new funding will grow Quantexa’s platform innovation efforts, elevate experiences for existing clients, create new partnerships and alliances, and allow the company to pursue selected M&A opportunities, as well as deepen its presence in North America.

This Series F investment comes just months after Quantexa achieved Centaur status, joining an elite group of SaaS businesses recognized for surpassing $100 million in ARR.

Vishal Marria, Founder and CEO of Quantexa, said:

AI is a once-in-a-generation technology transforming industries, redefining operations, and creating entirely new processes. From day one, Quantexa has been at the forefront of this revolution, helping enterprises create trusted, curated data to unlock AI's full potential. This latest investment reflects investors embracing our vision and committing to join our journey as we accelerate innovation, platform deployments, and amplify the value we deliver to clients and the broader ecosystem. With the continued support of our investors, including TVG, we are poised to push the boundaries of what's possible in AI and trusted data, reinforcing our leadership in this rapidly evolving landscape.

Christine Hockley, Managing Director, Funds, British Patient Capital, said,

British Patient Capital is the UK's largest domestic investor in venture and venture growth capital and the most active late-stage investor in UK deeptech. Quantexa exemplifies the kind of UK success story that needs access to the late-stage capital we can provide. We back innovation by providing long-term investment into high growth, high potential companies like Quantexa who want to build successful, world-class businesses. By identifying the UK's next generation of tech leaders and helping them to reach their potential, we in turn attract investment into sectors like AI, create jobs and drive wider economic growth.

George Mills, Director – Deeptech, Direct & Co-Investments, British Patient Capital, said,

We saw the potential in Quantexa years ago and have been proven right as they have hit the impressive milestones of becoming a unicorn and centaur. Not only have they created a powerful AI-based platform, but they are doing a fantastic job of building their company. We look forward to seeing where they go next.

Avid Larizadeh Duggan, Senior Managing Director, Private Capital, TVG, said:

Quantexa is at the forefront of AI-driven Decision Intelligence, transforming how enterprises and government agencies create trusted data foundations to drive mission critical business outcomes. At TVG, we seek to invest in high-growth, category defining companies with strong leadership and global impact. Quantexa's proven record, expanding customer base, and vision for AI innovation make it a perfect fit for our portfolio. We are excited to support the company's next phase of growth as it scales internationally and continues helping the world's leading companies establish cultures of confident decision making in the era of AI.

Further Information

Notes to editors

About British Patient Capital

British Patient Capital Limited is a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large-scale businesses. Launched in June 2018, British Patient Capital has more than £3bn of assets under management, investing in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more on British Patient Capital

British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.

British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.

The transaction described above does not constitute or imply any endorsement, warranty or recommendation by the UK government, the British Business Bank plc, its subsidiaries or any other party in respect of Quantexa.

About Quantexa 

Quantexa is a global AI, data and analytics software company pioneering Decision Intelligence to empower organizations to make trusted operational decisions with data in context. Using the latest advancements in AI, Quantexa’s Decision Intelligence platform helps organizations uncover hidden risk and new opportunities by unifying siloed data and turning it into the most trusted, reusable resource. It solves major challenges across data management, customer intelligence, KYC, financial crime, risk, fraud, and security, throughout the customer lifecycle

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. An independently commissioned Forrester TEI study on Quantexa's Decision Intelligence Platform found that customers saw a three-year 228% ROI. Founded in 2016, Quantexa now has over 800 employees and thousands of platform users working with billions of transactions and data points across the world. For more information visit Quantexa or follow us on LinkedIn 

About Teachers’ Venture Growth

Teachers’ Venture Growth (TVG) focuses on late-stage venture and growth equity investments in cutting-edge technology companies worldwide. We partner with founders with bold missions, looking to expand their product offering, scale geographically, and become the leaders in their markets. We bring long-term thinking and active investing to help build better businesses and a better world. We think globally and act locally through our direct presence across Asia, North America and Europe.

TVG is part of the Ontario Teachers' Pension Plan Board (Ontario Teachers'), a global investor with net assets of CAD 255.8 billion as of June 30, 2024. We invest in more than 50 countries in a broad array of assets including public and private equities, fixed income, credit, commodities, natural resources, infrastructure, real estate and venture growth to deliver retirement income for 340,000 working members and pensioners.

Our more than 450 investment professionals operate in key financial centres around the world and bring deep expertise in a broad range of sectors and industries. We are a fully funded defined benefit pension plan and have earned an annual total-fund net return of 9.3% since the plan's founding in 1990. At Ontario Teachers', we don't just invest to make a return, we invest to shape a better future for the teachers we serve, the businesses we back, and the world we live in. For more information, visit Teacher's Venture Growth and follow us on LinkedIn.

Quick links

Latest news